Back to Search
Start Over
Between-hospital variation in mortality and survival after glioblastoma surgery in the Dutch Quality Registry for Neuro Surgery
- Source :
- Journal of Neuro-Oncology, Journal of Neuro-Oncology, 144(2), 313-323. Kluwer Academic Publishers, Journal of Neuro-Oncology, 144(2), 313-323. Kluwer Academic, Journal of Neuro-Oncology, 144, 2, pp. 313-323, Journal of Neuro-Oncology, 144(2), 313-323. Springer, Cham, de Witt Hamer, P C, Ho, V K Y, Zwinderman, A H, Ackermans, L, Ardon, H, Boomstra, S, Bouwknegt, W, van den Brink, W A, Dirven, C M, van der Gaag, N A, van der Veer, O, Idema, A J S, Kloet, A, Koopmans, J, ter Laan, M, Verstegen, M J T, Wagemakers, M, Robe, P A J T & on behalf of the Quality Registry Neuro Surgery glioblastoma working group from the Dutch Society of Neurosurgery 2019, ' Between-hospital variation in mortality and survival after glioblastoma surgery in the Dutch Quality Registry for Neuro Surgery ', Journal of Neuro-Oncology, vol. 144, no. 2, pp. 313-323 . https://doi.org/10.1007/s11060-019-03229-5, JOURNAL OF NEURO-ONCOLOGY, 144(2), 313-323. SPRINGER, Journal of Neuro-Oncology, 144, 313-323, Journal of Neuro-Oncology, 144(2), 313-323, Journal of neuro-oncology, 144(2), 313-323. Kluwer Academic Publishers
- Publication Year :
- 2019
-
Abstract
- Purpose Standards for surgical decisions are unavailable, hence treatment decisions can be personalized, but also introduce variation in treatment and outcome. National registrations seek to monitor healthcare quality. The goal of the study is to measure between-hospital variation in risk-standardized survival outcome after glioblastoma surgery and to explore the association between survival and hospital characteristics in conjunction with patient-related risk factors. Methods Data of 2,409 adults with first-time glioblastoma surgery at 14 hospitals were obtained from a comprehensive, prospective population-based Quality Registry Neuro Surgery in The Netherlands between 2011 and 2014. We compared the observed survival with patient-specific risk-standardized expected early (30-day) mortality and late (2-year) survival, based on age, performance, and treatment year. We analyzed funnel plots, logistic regression and proportional hazards models. Results Overall 30-day mortality was 5.2% and overall 2-year survival was 13.5%. Median survival varied between 4.8 and 14.9 months among hospitals, and biopsy percentages ranged between 16 and 73%. One hospital had lower than expected early mortality, and four hospitals had lower than expected late survival. Higher case volume was related with lower early mortality (P = 0.031). Patient-related risk factors (lower age; better performance; more recent years of treatment) were significantly associated with longer overall survival. Of the hospital characteristics, longer overall survival was associated with lower biopsy percentage (HR 2.09, 1.34–3.26, P = 0.001), and not with academic setting, nor with case volume. Conclusions Hospitals vary more in late survival than early mortality after glioblastoma surgery. Widely varying biopsy percentages indicate treatment variation. Patient-related factors have a stronger association with overall survival than hospital-related factors. Electronic supplementary material The online version of this article (10.1007/s11060-019-03229-5) contains supplementary material, which is available to authorized users.
- Subjects :
- Male
Cancer Research
Survival
Logistic regression
Neurosurgical Procedures
0302 clinical medicine
Outcome Assessment, Health Care
Hospital Mortality
Prospective Studies
Registries
ELDERLY-PATIENTS
Netherlands
education.field_of_study
OUTCOMES
medicine.diagnostic_test
Brain Neoplasms
Middle Aged
Hospitals
3. Good health
Survival Rate
Neurology
Oncology
030220 oncology & carcinogenesis
GLIOMA
Female
Neurosurgery
NEWLY-DIAGNOSED GLIOBLASTOMA
medicine.medical_specialty
Funnel plot
RESECTION
Population
UNITED-STATES
03 medical and health sciences
All institutes and research themes of the Radboud University Medical Center
Glioma
Biopsy
medicine
Humans
Mortality
education
Proportional hazards model
business.industry
CARE
medicine.disease
PHASE-III
Surgery
Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]
TEMOZOLOMIDE ERA
Outcome assessment
PATTERNS
Clinical Study
Quality of health care
Neurology (clinical)
business
Glioblastoma
030217 neurology & neurosurgery
Follow-Up Studies
Subjects
Details
- ISSN :
- 15737373 and 0167594X
- Volume :
- 144
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Journal of neuro-oncology
- Accession number :
- edsair.doi.dedup.....003255e891028cf16074d9f5eae52e88